# A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy

> **NCT04455750** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 61 (actual)

## Conditions studied

- Castration-Resistant Prostate Carcinoma
- Metastatic Prostate Adenocarcinoma
- Stage IV Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** Rucaparib camsylate
- **DRUG:** Placebo
- **DRUG:** Leuprolide Acetate
- **DRUG:** Goserelin Acetate
- **DRUG:** Degarelix
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT04455750
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-14
- **Primary completion:** 2027-03-15
- **Final completion:** 2027-09
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2026-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04455750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04455750, "A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT04455750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*